VahatiCor Inc

Take a listen to Dr. Jean-Michel Paradis, an interventional cardiologist at the Quebec Heart and Lung Institute, Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval in Canada. Dr. Paradis and his team performed the first-in-human cases of the A-FLUX Coronary Sinus Reducer. ?? “So far, I’ve treated three patients with the A-FLUX device—two with severe obstructive coronary disease and one with microvascular dysfunction. All three procedures were successful, and the patients are doing very well.” Learn about his journey treating patients with severe obstructive coronary disease and microvascular dysfunction and why CMD is a hot topic in interventional cardiology. VahatiCor is committed to building the clinical evidence for this novel therapy and addressing the unmet needs of patients with coronary microvascular dysfunction. Watch the full interview below. #TCT2024 #InterventionalCardiology #MicrovascularDysfunction #AFLUX #Coronarysinusreducer #reducertherapy #CMD #Innovation #PatientCare #AFLUXReducer Disclaimer: VahatiCor’s A-Flux Reducer System? is not FDA-approved for commercial use.

Thank you, Cardiac Interventions Today, for shining a light on the A-FLUX Reducer System from VahatiCor and the unmet needs of patients with Coronary Microvascular Dysfunction (CMD). CMD, more prevalent in women, causes significant symptoms both at rest and during exertion. They have a real need for an effective treatment. We are committed to building the clinical evidence for this novel therapy. #VahatiCor #AFLUXReducer #Cardiology #CMD #microvascular #coronary #CoronaryMicrovascularDysfunction #MedicalInnovation #PatientCare #interventionalcardiology

In our recent conversation at TCT, Dr. Francesco Giannini shared key insights on his work with coronary sinus reducer therapy. With over a decade of experience in the field, Dr. Giannini discussed promising results from the compassionate use of the A-FLUX system. He noted that, "At one month, most patients showed significant angina relief, with these improvements in quality of life sustained at six months." Catch the full interview for more on Dr. Francesco Giannini's perspective on CMD treatment advancements and what’s next for patient care. #TCT2024 #Cardiology #CMD #AFLUX #VahatiCor #microvascular #CoronaryMicrovascularDysfunction #HealthcareInnovation #interventionalcardiology

Coronary microvascular dysfunction is a significant unmet need impacting the quality of life of many patients. Listen to Dr. Samit Shah MD, PhD discuss patient symptoms and the importance of gathering clinical evidence supporting coronary sinus reducer therapy. #TCT2024 #Cardiology #CMD #AFLUXReducer #VahatiCor #coronary #coronarymicrovasculardysfunction #microvascular #coronarysinusreducer #interventionalcardiology

This morning, Dr. Francesco Giannini delivered a powerful presentation on the first-in-man experience of the A-FLUX coronary sinus reducer. He shared the positive results from the compassionate use study, showing us how this therapy addresses one of the unmet needs in cardiology today: coronary microvascular dysfunction. A huge thank you to Dr. Francesco Giannini and the team behind the data. #TCT2024 #Cardiology #CMD #AFLUXReducer #VahatiCor #coronary #coronarymicrovasculardysfunction #microvascular #coronarysinusreducer

A new therapy on the horizon for microvascular patients? Join Dr. Francesco Giannini tomorrow morning as he presents the first-in-man experience of the A-FLUX Coronary Sinus Reducer. This session will review how the first patients, including coronary microvascular patients, were treated with A-FLUX therapy and how it impacted their symptoms. Come and see! ???October 30, 2024, 9:24 AM – 9:29 AM ?? Walter E. Washington Convention Center | Moderated Abstracts Station 6 #TCT2024 #Cardiology #CMD #AFLUXReducer #VahatiCor #coronary #coronarymicrovasculardysfunction #microvascular #coronarysinusreducer #interventionalcardiology

We’re thrilled to share positive results from our compassionate use study of the A-FLUX Reducer System?, which showed significant symptom relief for patients with coronary microvascular dysfunction (CMD) and persistent obstructive coronary artery disease. Link to the press release here: https://lnkd.in/dScnATSz Thank you, Dr. Samit Shah and Dr. Tim Van de Hoef, for leading the SERRA I study with the A-FLUX Coronary Sinus Reducer. It is an important first step in our journey to help patients suffering from coronary microvascular dysfunction. #VahatiCor #AFLUXReducer #Cardiology #CMD #HeartHealth #MedicalInnovation #ClinicalResearch

Dr. Manel Sabate presented today the excellent results of the first patient with coronary microvascular dysfunction treated with VahatiCor’s A-FLUX Coronary Sinus Reducer. A heartfelt thank you to Dr. Sabate and to the whole team at the Hospital Clínic de Barcelona for this important step in addressing this underdiagnosed and undertreated patient group. #TCT2024 #Cardiology #CoronaryMicrovascularDysfunction #CMD #AFLUXReducer #VahatiCor #HeartHealth #InterventionalCardiology #PatientCare #HealthcareAdvancement

Today’s the day! We’re giving the stage to Dr. Manel Sabate as he shares insights on the potential of the A-FLUX Reducer at TCT 2024. Expect a close look at how this next-generation technology could address the challenges of coronary microvascular dysfunction (CMD). Don’t miss out! ?? October 27, 2024, 2:55 PM – 3:00 PM ?? Walter E. Washington Convention Center | Innovation & Exhibit Hall | Presentation Theater 1 #TCT2024 #Cardiology #CMD #AFLUXReducer #VahatiCor #coronary #coronarymicrovasculardysfunction #microvascular #coronarysinusreducer #interventionalcardiology #HeartHealth #medicalinnovation #HeartDisease

Want to get a glimpse into the future and how you could be treating your patients with Coronary Microvascular Dysfunction? Mark your calendars during #TCT2024 and learn about the A-FLUX Coronary Sinus Reducer therapy from VahatiCor Inc! Up to 70% of patients presenting at angiography have unobstructed epicardial vessels. Half of symptomatic patients with non-obstructive disease have microvascular impairment. These many patients, mostly younger women, are underdiagnosed and have limited effective therapies. At VahatiCor Inc, we’re on a mission to shed light on this condition and work with eminent centers to gather the clinical evidence that will transform how it is treated. This year at #TCT, you can catch up on the latest data of the A-FLUX Coronary Sinus Reducer System. Mark your calendars for these key sessions: ??? October 27, 2024 | 2:55 PM – 3:00 PM Speaker: Dr. Manel Sabate Session: Improving Coronary Microcirculatory Function with the A-FLUX Next-Gen Reducer Location: Presentation Theater 1 ??? October 30, 2024 | 9:24 AM – 9:29 AM Speaker: Dr. Francesco Giannini Session: First-in-Man Experience with the Self-Expandable A-FLUX Coronary Sinus Reducer Location: Moderated Abstracts Station 6 We want to extend a heartfelt thank you to Drs Manel Sabate, Francesco Giannini, Rishi Puri, and Omar Abdul-Jawad Altisent for their contributions to this critical work. Together, we are pushing forward in our quest to help patients suffering from Coronary Microvascular Dysfunction. Looking forward to seeing you at TCT! #TCT2024 #Cardiology #CMD #AFLUXReducer #VahatiCor #coronary #coronarymicrovasculardysfunction #microvascular #coronarysinusreducer #interventionalcardiology